The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours.
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Lilly/ImClone; Novartis; SERVIER
 
Chris Garratt
Employment - Orion
 
Kaisa Laapas
Employment - Orion
 
Hanna Leskinen
Employment - Orion
 
Harry Bjorklund
Employment - Orion
 
Angela Ruck
Employment - Orion
 
Katriina Peltola
Employment - Orion
Stock and Other Ownership Interests - Faron Pharmaceuticals
Honoraria - Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Baxalta; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Analia Azaro
No Relationships to Disclose
 
Eduardo Castanon-Alvarez
No Relationships to Disclose
 
Christophe Massard
No Relationships to Disclose
 
Petri Bono
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Orion; Pfizer
Research Funding - Novartis